科室与专家门诊
妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都有院区。医务人员掌握数几十种专业技能，齐心协力，确保高品质治疗与成功康复。
研究
Researchers at Mayo Clinic are studying new ways to diagnose and treat hilar cholangiocarcinoma. This research is conducted as part of the Division of Gastroenterology and Hepatology in coordination with Mayo Clinic Cancer Center.
Mayo Clinic Cancer Center receives funding from the National Cancer Institute (NCI) and is an NCI-designated comprehensive cancer center — recognition for an institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.
Areas of research include:
- Studying the association of aspirin and statin medicines with a reduced risk of cholangiocarcinoma.
- Investigating the molecular genetics of tumors and identifying biomarkers, which may aid in early diagnosis or lead to new targeted therapies.
- Doing clinical trials for new targeted therapies. These trials are possible because of Mayo Clinic's high patient volume for primary sclerosing cholangitis and bile duct cancer.
- Expanding surgical options and refining techniques, including vessel and bile duct reconstruction, to widen the number of people who may qualify for curative approaches.
- Proving that the biomarker CA 19-9 is useful for staging cholangiocarcinoma and understanding the prognosis for people with the disease.
Publications
See a list of publications about cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.